This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shinomiya, N. Articles by Vande Woude, G. F. Search for Related Content PubMed PubMed Citation Articles by Shinomiya, N. Articles by Vande Woude, G. F.

RNA Interference Reveals that Ligand-Independent Met Activity Is Required for Tumor Cell Signaling and Survival

¹ Laboratory of Molecular Oncology, Van Andel Research Institute, Grand Rapids, Michigan, ² Purdue University, and ³ The Gerald P. Murphy Cancer Foundation, West Lafayette, Indiana

Hepatocyte growth factor/scatter factor-Met signaling has been implicated in tumor growth, invasion, and metastasis. Suppression of this signaling pathway by targeting the Met protein tyrosine kinase may be an ideal strategy for suppressing malignant tumor growth. Using RNA interference technology and adenovirus vectors carrying small-interfering RNA constructs (Ad Met small-interfering RNA) directed against mouse, canine, and human Met, we can knock down c-met mRNA. We show a dramatic dependence on Met in both ligand-dependent and ligand-independent mouse, canine, and human tumor cell lines. Mouse mammary tumor (DA3) cells and Met-transformed NIH3T3 (M114) cells, as well as both human and canine prostate cancer (PC-3 and TR6LM, human sarcoma (SK-LMS-1), glioblastoma (DBTRG), and gastric cancer (MKN45) cells, all display a dramatic reduction of Met expression after infection with Ad Met small-interfering RNA. In these cells, we observe suppression of tumor cell growth and viability in vitro as well as inhibition of hepatocyte growth factor/scatter factor-mediated scattering and invasion in vitro, whether Met activation was ligand dependent or not. Importantly, Ad Met small-interfering RNA led to apoptotic cell death in many of the tumor cell lines, especially DA3 and MKN45, but did not adversely affect MDCK canine kidney cells. Met small-interfering RNA also abrogated downstream Met signaling to molecules such as Akt and p44/42 mitogen-activated protein kinase. We further show that intratumoral infection with c-met small-interfering RNA adenovirus results in a substantial reduction in tumor growth. Thus, Met small-interfering RNA adenoviruses are reliable tools for studying Met function and raise the possibility of their application for cancer therapy.

This article has been cited by other articles:

				Z. Tiran, A. Oren, C. Hermesh, G. Rotman, Z. Levine, H. Amitai, T. Handelsman, M. Beiman, A. Chen, D. Landesman-Milo, et al. A Novel Recombinant Soluble Splice Variant of Met Is a Potent Antagonist of the Hepatocyte Growth Factor/Scatter Factor-Met Pathway Clin. Cancer Res., July 15, 2008; 14(14): 4612 - 4621. [Abstract] [Full Text] [PDF]

				S. Kim, U. J. Lee, M. N. Kim, E.-J. Lee, J. Y. Kim, M. Y. Lee, S. Choung, Y. J. Kim, and Y.-C. Choi MicroRNA miR-199a* Regulates the MET Proto-oncogene and the Downstream Extracellular Signal-regulated Kinase 2 (ERK2) J. Biol. Chem., June 27, 2008; 283(26): 18158 - 18166. [Abstract] [Full Text] [PDF]

				K. L. Mueller, L. A. Hunter, S. P. Ethier, and J. L. Boerner Met and c-Src Cooperate to Compensate for Loss of Epidermal Growth Factor Receptor Kinase Activity in Breast Cancer Cells Cancer Res., May 1, 2008; 68(9): 3314 - 3322. [Abstract] [Full Text] [PDF]

				C. M. Stellrecht, C. J. Phillip, F. Cervantes-Gomez, and V. Gandhi Multiple Myeloma Cell Killing by Depletion of the MET Receptor Tyrosine Kinase Cancer Res., October 15, 2007; 67(20): 9913 - 9920. [Abstract] [Full Text] [PDF]

				M. J. Edick, L. Tesfay, L. E. Lamb, B. S. Knudsen, and C. K. Miranti Inhibition of Integrin-mediated Crosstalk with Epidermal Growth Factor Receptor/Erk or Src Signaling Pathways in Autophagic Prostate Epithelial Cells Induces Caspase-independent Death Mol. Biol. Cell, July 1, 2007; 18(7): 2481 - 2490. [Abstract] [Full Text] [PDF]

				N. Puri, S. Ahmed, V. Janamanchi, M. Tretiakova, O. Zumba, T. Krausz, R. Jagadeeswaran, and R. Salgia c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma Clin. Cancer Res., April 1, 2007; 13(7): 2246 - 2253. [Abstract] [Full Text] [PDF]

				B. Lutterbach, Q. Zeng, L. J. Davis, H. Hatch, G. Hang, N. E. Kohl, J. B. Gibbs, and B.-S. Pan Lung Cancer Cell Lines Harboring MET Gene Amplification Are Dependent on Met for Growth and Survival Cancer Res., March 1, 2007; 67(5): 2081 - 2088. [Abstract] [Full Text] [PDF]

				K. Sawada, A. R. Radjabi, N. Shinomiya, E. Kistner, H. Kenny, A. R. Becker, M. A. Turkyilmaz, R. Salgia, S. D. Yamada, G. F. Vande Woude, et al. c-Met Overexpression Is a Prognostic Factor in Ovarian Cancer and an Effective Target for Inhibition of Peritoneal Dissemination and Invasion Cancer Res., February 15, 2007; 67(4): 1670 - 1679. [Abstract] [Full Text] [PDF]

				Y. Miyata, H. Kanetake, and S. Kanda Presence of Phosphorylated Hepatocyte Growth Factor Receptor/c-Met Is Associated with Tumor Progression and Survival in Patients with Conventional Renal Cell Carcinoma. Clin. Cancer Res., August 15, 2006; 12(16): 4876 - 4881. [Abstract] [Full Text] [PDF]

				A. Strat, L. Gao, T. Utsuki, B. Cheng, S. Nuthalapaty, J. M. Mathis, Y. Odaka, and T. Giordano Specific and nontoxic silencing in mammalian cells with expressed long dsRNAs Nucleic Acids Res., August 11, 2006; 34(13): 3803 - 3810. [Abstract] [Full Text] [PDF]

				M. Mazzone and P. M. Comoglio The Met pathway: master switch and drug target in cancer progression FASEB J, August 1, 2006; 20(10): 1611 - 1621. [Abstract] [Full Text] [PDF]

				N. Lasagna, O. Fantappie, M. Solazzo, L. Morbidelli, S. Marchetti, G. Cipriani, M. Ziche, and R. Mazzanti Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. Cancer Res., March 1, 2006; 66(5): 2673 - 2682. [Abstract] [Full Text] [PDF]

				R. Jagadeeswaran, P. C. Ma, T. Y. Seiwert, S. Jagadeeswaran, O. Zumba, V. Nallasura, S. Ahmed, R. Filiberti, M. Paganuzzi, R. Puntoni, et al. Functional Analysis of c-Met/Hepatocyte Growth Factor Pathway in Malignant Pleural Mesothelioma Cancer Res., January 1, 2006; 66(1): 352 - 361. [Abstract] [Full Text] [PDF]

				H. Takeuchi, J. Kim, A. Fujimoto, N. Umetani, T. Mori, A. Bilchik, R. Turner, A. Tran, C. Kuo, and D. S.B. Hoon X-Linked Inhibitor of Apoptosis Protein Expression Level in Colorectal Cancer Is Regulated by Hepatocyte Growth Factor/C-Met Pathway via Akt Signaling Clin. Cancer Res., November 1, 2005; 11(21): 7621 - 7628. [Abstract] [Full Text] [PDF]

				S.-Z. Zhang, F.-Y. Pan, J.-F. Xu, J. Yuan, S.-Y. Guo, G. Dai, B. Xue, W.-G. Shen, C.-J. Wen, D.-H. Zhao, et al. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo Mol. Cancer Ther., October 1, 2005; 4(10): 1577 - 1584. [Abstract] [Full Text] [PDF]

				R. V. Hay, B. Cao, R. S. Skinner, Y. Su, P. Zhao, M. F. Gustafson, C.-N. Qian, B. T. Teh, B. S. Knudsen, J. H. Resau, et al. Nuclear Imaging of Met-Expressing Human and Canine Cancer Xenografts with Radiolabeled Monoclonal Antibodies (MetSeekTM) Clin. Cancer Res., October 1, 2005; 11(19): 7064s - 7069s. [Abstract] [Full Text] [PDF]